• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

World distribution of factor V Leiden.

作者信息

Rees D C, Cox M, Clegg J B

机构信息

MRC Molecular Haematology Unit, John Radcliffe Hospital, Headington, Oxford, UK.

出版信息

Lancet. 1995 Oct 28;346(8983):1133-4. doi: 10.1016/s0140-6736(95)91803-5.

DOI:10.1016/s0140-6736(95)91803-5
PMID:7475606
Abstract

We have analysed 3380 chromosomes (1690 unrelated individuals) from twenty-four populations for the presence of factor V Leiden, an important risk factor in venous thromboembolism. The allele frequency in 618 Europeans was 4.4%, with the highest prevalence among Greeks (7%). It was 0.6% in Asia Minor. Factor V Leiden was not found in any of 1600 chromosomes from Africa, Southeast Asia, Australasia, and the Americas. This distribution may partly explain the rarity of thromboembolic disease in these populations. The high prevalence in Europeans suggests that screening for this mutation should be considered in some circumstances.

摘要

相似文献

1
World distribution of factor V Leiden.
Lancet. 1995 Oct 28;346(8983):1133-4. doi: 10.1016/s0140-6736(95)91803-5.
2
World distribution of factor V Leiden.凝血因子V莱顿突变的全球分布。
Lancet. 1996 Feb 17;347(8999):481-2. doi: 10.1016/s0140-6736(96)90064-1.
3
The population genetics of factor V Leiden (Arg506Gln).凝血因子V莱顿突变(Arg506Gln)的群体遗传学
Br J Haematol. 1996 Dec;95(4):579-86. doi: 10.1046/j.1365-2141.1996.d01-1954.x.
4
Born to clot: the European burden.天生易凝血:欧洲的负担。
Br J Haematol. 1999 May;105(2):564-6.
5
Population genetics of factor V Leiden in Europe.欧洲凝血因子V莱顿突变的群体遗传学
Blood Cells Mol Dis. 2001 Mar-Apr;27(2):362-7. doi: 10.1006/bcmd.2001.0388.
6
World distribution of factor V Leiden mutation.凝血因子V莱顿突变的全球分布。
Lancet. 1996 Jan 6;347(8993):58-9.
7
Frequency of factor V Leiden in Turkey.土耳其因子V莱顿突变的发生率。
Int J Hematol. 1996 Oct;64(3-4):291-2.
8
The G1691A mutation of the coagulation factor V gene (factor V Leiden) is rare in Chinese: an analysis of 618 individuals.
Hum Genet. 1996 Aug;98(2):176-7. doi: 10.1007/s004390050184.
9
Prevalence of factor V Leiden mutation in various populations.不同人群中凝血因子V莱顿突变的患病率。
Genet Epidemiol. 1997;14(4):403-11. doi: 10.1002/(SICI)1098-2272(1997)14:4<403::AID-GEPI5>3.0.CO;2-3.
10
Factor V Leiden and thermolabile methylenetetrahydrofolate reductase in extreme old age.高龄人群中的因子V莱顿突变和不耐热亚甲基四氢叶酸还原酶
Thromb Haemost. 1997 Nov;78(5):1357-9.

引用本文的文献

1
The prevalence of FV Hong Kong in patients with thrombotic disorders in South China.华南血栓性疾病患者中FV香港型的患病率。
J Thromb Thrombolysis. 2025 Aug 29. doi: 10.1007/s11239-025-03168-1.
2
Association of the Coagulation Factor V c.3865T>G Mutation with Genetic and Regional Susceptibility to Cerebral Venous and Sinus Thrombosis in Xiangyang.凝血因子V基因c.3865T>G突变与襄阳地区脑静脉窦血栓形成的遗传易感性和区域易感性的关联
Vasc Health Risk Manag. 2025 Aug 13;21:645-653. doi: 10.2147/VHRM.S518609. eCollection 2025.
3
Association of FV G1691A, FV H1299R, and FII G20210A variations with thrombosis and coronary artery disease (CAD): A population-based study.
凝血因子V G1691A、凝血因子V H1299R及凝血因子II G20210A变异与血栓形成及冠状动脉疾病(CAD)的关联:一项基于人群的研究。
J Med Biochem. 2025 Jun 13;44(3):447-452. doi: 10.5937/jomb0-39668.
4
Development and validation of a genetic probability for venous thromboembolism.静脉血栓栓塞症遗传概率的制定与验证
Res Pract Thromb Haemost. 2025 Apr 27;9(4):102876. doi: 10.1016/j.rpth.2025.102876. eCollection 2025 May.
5
Inherited thrombophilias and stillbirth: a systematic review and meta- analysis.遗传性血栓形成倾向与死产:一项系统评价和荟萃分析。
Arch Gynecol Obstet. 2025 Mar 14. doi: 10.1007/s00404-025-07989-6.
6
Efficacy and safety of anti-Xa direct oral anticoagulants vs. warfarin in patients homozygous for Factor V Leiden and prothrombin G20210A mutations.抗Xa直接口服抗凝剂与华法林在携带因子V莱顿纯合子和凝血酶原G20210A突变患者中的疗效和安全性比较
J Thromb Thrombolysis. 2025 Feb;58(2):188-198. doi: 10.1007/s11239-025-03069-3. Epub 2025 Feb 1.
7
Incidence of Venous Thromboembolism after Primary Total Hip Arthroplasty with Mechanical Prophylaxis in Hong Kong Chinese.香港华人行初次全髋关节置换术后采用机械预防措施时静脉血栓栓塞的发生率
Hip Pelvis. 2024 Jun 1;36(2):108-119. doi: 10.5371/hp.2024.36.2.108.
8
Thrombophilia Testing: from Genetic Predisposition to Discrimination.血栓形成倾向检测:从遗传易感性到歧视
TH Open. 2024 Apr 8;8(2):e177-e180. doi: 10.1055/a-2284-4285. eCollection 2024 Apr.
9
Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank.在 FinnGen 和 UK Biobank 中,单一和双重杂合子携带因子 V Leiden 和凝血酶原 G20210A 的血栓形成风险。
Blood. 2024 Jun 6;143(23):2425-2432. doi: 10.1182/blood.2023023326.
10
Fibrinolysis biomarker, thrombin, and activated protein C level alterations after coagulation activation depend on type of thrombophilia and clinical phenotype.凝血激活后纤维蛋白溶解生物标志物、凝血酶和活化蛋白C水平的改变取决于血栓形成倾向的类型和临床表型。
Res Pract Thromb Haemost. 2024 Feb 15;8(2):102351. doi: 10.1016/j.rpth.2024.102351. eCollection 2024 Feb.